Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Other Long-Term Assets
Apontis Pharma AG
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Other Long-Term Assets
€4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Other Long-Term Assets
$2.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Other Long-Term Assets
€6.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Other Long-Term Assets
€1.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Other Long-Term Assets
-€2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Other Long-Term Assets?
Other Long-Term Assets
4m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Other Long-Term Assets amounts to 4m EUR.
What is Apontis Pharma AG's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
43%
Over the last year, the Other Long-Term Assets growth was 816%. The average annual Other Long-Term Assets growth rates for Apontis Pharma AG have been 43% over the past three years .
You don't have any saved screeners yet